gsk239512
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2007 (NCT00474513)
Timeline
Indications
Mechanism of action
- Histamine H3 receptorANTAGONIST
HRH3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C1CCCN1c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1- Mol. weight
- 377.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3092650 ↗
Also known as
- gsk239512
- gsk239512
- gsk239512
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01772199 | Phase 2 | Feb 1, 2013 | GlaxoSmithKline |
| NCT01802931 | Phase 1 | Jan 1, 2013 | GlaxoSmithKline |
| NCT01009060 | Phase 2 | Dec 1, 2009 | GlaxoSmithKline |
| NCT01009255 | Phase 2 | Nov 2, 2009 | GlaxoSmithKline |
| NCT00675090 | Phase 1 | Feb 1, 2008 | GlaxoSmithKline |
| NCT00474513 | Phase 1 | Mar 1, 2007 | GlaxoSmithKline |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2007 |
1 organizations
Page 1 / 1